Slow-reacting substances and asthma: leukotrienes may hold the key to asthma therapy.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000818:Animals; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000378:metabolism; D001249:Asthma / Q000188:drug therapy*; D012898:Autacoids / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000378:metabolism; D004205:Cromolyn Sodium / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008657:Metabolic Clearance Rate; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D013189:SRS-A / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000378:metabolism / Q000031:analogs & derivatives; D013806:Theophylline / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D001095:Arachidonic Acids; D012898:Autacoids; D013189:SRS-A; C025492:leukotriene C-2; D013806:Theophylline; D004205:Cromolyn Sodium